The 2-Minute Rule for Atabecestat
All enrolled patients who obtained at the least 1 dose of zosuquidar or placebo through induction have been monitored with the incidence of adverse occasions (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse activities were being linked to the period of prolonged and important myelosuppression as is expected with induction c